Nodal signaling pathway

The **Nodal signaling pathway** is a signal transduction cascade belonging to the transforming growth factor beta (TGFβ) superfamily, crucial for embryonic patterning, cell differentiation, mesoendoderm induction, and left-right axis specification in vertebrates and other chordates[1][3][5]. Signaling is initiated by Nodal protein binding to activin type I and II receptors, which are serine/threonine kinases, leading to phosphorylation of intracellular Smad2 and Smad3 proteins; these form complexes with Smad4 and translocate to the nucleus to modulate transcription of target genes including NODAL itself, Lefty, and Cerberus[1][3]. Antagonists such as Lefty and Cerberus are key regulators of pathway amplitude and spatial specificity, maintaining proper developmental outcomes[1]. Although **Nodal signaling** is primarily studied in developmental biology, dysregulation of this axis is implicated in several cancers; notably, aberrant Nodal expression is a hallmark of aggressive melanoma and endometrial cancer, contributing to tumor cell plasticity, invasiveness, and metastatic potential[2][4]. In cancer research, the pathway has drawn attention as a potential therapeutic target, with preclinical data supporting efficacy of small molecule inhibitors and anti-Nodal antibodies in reducing tumor growth and inducing apoptosis in Nodal-expressing tumors[2][4]. Because the target is a multicompartment signaling cascade rather than a defined molecular entity (such as a receptor or enzyme), the **Nodal signaling pathway** itself is not considered a canonical drug target, though its key components are targeted pharmacologically in research and early translational contexts[2][5].

Other names

Nodal pathwayNodal/TGF-beta pathwayNodal-Activin/Smad2/3 pathway

Inhibition of Nodal signaling via kinase inhibition[2][5] Direct antibody-mediated Nodal protein blockade[2]